Global Tyrosine Kinase Inhibitors Market, By Type (BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors, Others), Application (Chronic Myeloid Leukemia (CML), Lung Cancer, Breast Cancer, Others), End Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) Industry Trends and Forecast to 2028
The tyrosine kinase inhibitors market is expected to witness market growth at a rate of 5.9% in the forecast period of 2021 to 2028. Data Bridge Market Research report on tyrosine kinase inhibitors market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. The rapid advancements in the healthcare sector globally is escalating the growth of tyrosine kinase inhibitors market.
Tyrosine kinase inhibitors refer to the type of drugs inhibiting the proteins called tyrosine kinases. These proteins are defined as the enzyme that activates signal transduction cascades that is majorly responsible for cell functions such as cell signaling, growth and division. The abnormal formation and release of these enzymes result in facilitating the growth of cancer.
The increase in prevalence of cancer incidence across the globe acts as one of the major factors driving the growth of tyrosine kinase inhibitors market. The rise in adoption of tyrosine kinase inhibitors over traditional therapies owning to the advantages such as ease of oral administration, and the ability to target multiple cellular survival pathways, and increase in demand for innovative therapeutics accelerate the market growth. The increase in investment from pharmaceutical companies, and use of cell processes in regulating various cell activities in cancer further influence the market. Additionally, rise in healthcare expenditure, growth of awareness, increase in the population, improved healthcare infrastructure and advancements in cancer treatments positively affect the tyrosine kinase inhibitors market. Furthermore, rise in demand for novel therapies and several innovations, and advanced therapeutics extend profitable opportunity to the market players in the forecast period of 2021 to 2028.
On the other hand, high costs associated with development and drug post-approval, and stringent regulations are expected to obstruct the market growth. Side effects associated with tyrosine kinase inhibitor drugs such as fatigue, muscle cramps, vomiting among others, and lack of technical professionals are projected to challenge the tyrosine kinase inhibitors market in the forecast period of 2021-2028.
This tyrosine kinase inhibitors market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on tyrosine kinase inhibitors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Tyrosine Kinase Inhibitors Market Scope and Market Size
The tyrosine kinase inhibitors market is segmented on the basis of type, application, end users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of type, the tyrosine kinase inhibitors market is segmented into BCR-ABL tyrosine kinase inhibitor, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, vascular endothelial growth factor (VEGFR) tyrosine kinase inhibitors and others.
- On the basis of application, the tyrosine kinase inhibitors market is segmented into chronic myeloid leukemia (CML), lung cancer, breast cancer and others.
- On the basis of end users, the tyrosine kinase inhibitors market is segmented into hospitals, homecare, specialty clinics and others.
- On the basis of distribution channel, the tyrosine kinase inhibitors market is segmented into hospital pharmacy, online pharmacy, retail pharmacy and others.
Tyrosine Kinase Inhibitors Market Country Level Analysis
The tyrosine kinase inhibitors market is analyzed and market size insights and trends are provided by country, type, application, end users and distribution channel as referenced above.
The countries covered in the tyrosine kinase inhibitors market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the tyrosine kinase inhibitors market because of the developed and well-structured health care system within the region. Asia-Pacific is expected to witness significant growth during the forecast period of 2021 to 2028 due to the large population and high prevalence of cancer in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The tyrosine kinase inhibitors market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Tyrosine Kinase Inhibitors Market Share Analysis
The tyrosine kinase inhibitors market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to tyrosine kinase inhibitors market.
The major players covered in the tyrosine kinase inhibitors market report are F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Ascentage Pharma, AstraZeneca, Eisai Co., Ltd., Novartis AG, Sanofi, Bristol-Myers Squibb Company, Genentech, Inc., Pfizer Inc., Merck & Co., Inc., Suzhou Zelgen Biopharmaceuticals Co., Ltd., Celldex Therapeutics, Exelixis, Inc., Sino Biological Inc., AB Science, Bayer AG Deciphera Pharmaceuticals, Inc., and Johnson & Johnson Services, Inc., among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.